Co-Diagnostics, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
CODX$0.32+24.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Product revenue | $770,048 | $991,473 |
| Grant revenue | 3,145,112 | 5,820,565 |
| Total revenue | 3,915,160 | 6,812,038 |
| Cost of revenue | 999,124 | 4,184,949 |
| Gross profit | 2,916,036 | 2,627,089 |
| Operating expenses | ||
| Sales and marketing | 4,483,339 | 6,860,815 |
| General and administrative | 16,157,152 | 14,279,441 |
| Research and development | 20,979,589 | 22,962,593 |
| Depreciation and amortization | 1,377,266 | 1,230,474 |
| Total operating expenses | 42,997,346 | 45,333,323 |
| Loss from operations | (40,081,310) | (42,706,234) |
| Other income, net | ||
| Interest income, net | 1,091,825 | 1,161,913 |
| Realized gain on investments | 870,745 | 2,243,059 |
| Gain (loss) on disposition of assets | 8,291 | (2,578) |
| Gain on remeasurement of acquisition contingencies | 714,876 | 1,092,581 |
| Gain (loss) on equity method investment in joint venture | (186,067) | 100,703 |
| Total other income, net | 2,499,670 | 4,595,678 |
| Loss before income taxes | (37,581,640) | (38,110,556) |
| Income tax provision (benefit) | 57,368 | (2,777,691) |
| Net loss | $(37,639,008) | $(35,332,865) |
| Other comprehensive loss | ||
| Change in net unrealized gains on marketable securities, net of tax | 271,743 | (146,440) |
| Total other comprehensive income (loss) | $271,743 | $(146,440) |
| Comprehensive loss | $(37,367,265) | $(35,479,305) |
| Loss per common share: | ||
| Basic and Diluted | $(1.24) | $(1.20) |
| Weighted average shares outstanding: | ||
| Basic and Diluted | 30,335,350 | 29,346,599 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.